GE HealthCare’s MIM Software has launched MIM Symphony HDR Prostate, an advanced solution designed to enhance high dose-rate (HDR) brachytherapy for prostate cancer treatment.

This innovative software integrates magnetic resonance imaging (MRI) directly into live ultrasound procedures, aiming to improve treatment accuracy and patient outcomes.

HDR brachytherapy traditionally involves implanting radioactive sources into the prostate using computed tomography (CT) or ultrasound guidance.

However, incorporating MRI can offer clearer visualization of tumors and critical structures, potentially reducing side effects. MIM Symphony HDR Prostate addresses the challenge of aligning preoperative MRI images with real-time ultrasound during procedures.

The benefits of MRI guidance: "MRI enables more precise treatments and minimizes risks to nearby organs. MIM Symphony HDR Prostate facilitates confident needle placement by aligning MRI contours with ultrasound in real time."

Key features include:

• Alignment of MRI contours with live ultrasound images for precise needle placement.
• Correction of orientation differences between MRI and ultrasound using the ReSlicer tool.
• Automated digitization and review of needles on planning images to ensure accurate treatment delivery.

The solution's role in advancing precision care: "MIM Symphony HDR Prostate reflects commitment to innovation in brachytherapy, empowering clinicians to deliver safer, more informed treatments."

This addition expands GE HealthCare’s MIM Software portfolio, enhancing radiation oncology solutions and interoperability across healthcare systems.

For more information, visit MIMSoftware.com and GEHealthCare.com or explore MIM Symphony HDR Prostate at upcoming global conferences.

 

 

 

 

Source: gehealthcare.com

Report Abuse